CN103232545A - Recombination porcine interferon alpha1-Fc fusion protein as well as coding gene and expression method thereof - Google Patents
Recombination porcine interferon alpha1-Fc fusion protein as well as coding gene and expression method thereof Download PDFInfo
- Publication number
- CN103232545A CN103232545A CN2013101828556A CN201310182855A CN103232545A CN 103232545 A CN103232545 A CN 103232545A CN 2013101828556 A CN2013101828556 A CN 2013101828556A CN 201310182855 A CN201310182855 A CN 201310182855A CN 103232545 A CN103232545 A CN 103232545A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- pig interferon
- interferon
- reorganization
- alpha1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 23
- 102000014150 Interferons Human genes 0.000 title abstract description 24
- 108010050904 Interferons Proteins 0.000 title abstract description 24
- 229940079322 interferon Drugs 0.000 title abstract description 24
- 108020001507 fusion proteins Proteins 0.000 title abstract description 16
- 102000037865 fusion proteins Human genes 0.000 title abstract description 15
- 238000005215 recombination Methods 0.000 title abstract description 8
- 230000006798 recombination Effects 0.000 title abstract description 8
- 238000004153 renaturation Methods 0.000 claims abstract description 28
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 26
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 14
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims description 138
- 108010047761 Interferon-alpha Proteins 0.000 claims description 138
- 230000004927 fusion Effects 0.000 claims description 130
- 230000008521 reorganization Effects 0.000 claims description 129
- 101000959787 Sus scrofa Interferon alpha-1 Proteins 0.000 claims description 54
- 241000894006 Bacteria Species 0.000 claims description 48
- 230000000968 intestinal effect Effects 0.000 claims description 35
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 28
- 238000001556 precipitation Methods 0.000 claims description 28
- 239000000872 buffer Substances 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 14
- 238000000703 high-speed centrifugation Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 235000015097 nutrients Nutrition 0.000 claims description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 102000057593 human F8 Human genes 0.000 claims description 9
- 229940047431 recombinate Drugs 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- 238000013016 damping Methods 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 5
- 239000012139 lysis buffer Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010612 desalination reaction Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 206010010254 Concussion Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000009514 concussion Effects 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 abstract description 17
- 230000004071 biological effect Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 2
- 230000009465 prokaryotic expression Effects 0.000 abstract description 2
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 148
- 108020004705 Codon Proteins 0.000 description 37
- 230000009182 swimming Effects 0.000 description 36
- 239000000523 sample Substances 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 18
- 239000006166 lysate Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 11
- 101710135378 pH 6 antigen Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000975 dye Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001073 sample cooling Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Cis-acting elements | Before the optimization | After the optimization |
E.coli_RBS(AGGAGG) | 4 | 0 |
PolyT(TTTTTT) | 0 | 0 |
PolyA(AAAAAAA) | 0 | 0 |
Ch site (GCTGGTGG) | 0 | 0 |
T7Cis(ATCTGTT) | 0 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310182855.6A CN103232545B (en) | 2013-05-16 | 2013-05-16 | A kind of Recombinant Swine Interferon α1-Fc fusion rotein and encoding gene thereof and expression method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310182855.6A CN103232545B (en) | 2013-05-16 | 2013-05-16 | A kind of Recombinant Swine Interferon α1-Fc fusion rotein and encoding gene thereof and expression method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103232545A true CN103232545A (en) | 2013-08-07 |
CN103232545B CN103232545B (en) | 2016-03-16 |
Family
ID=48880621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310182855.6A Active CN103232545B (en) | 2013-05-16 | 2013-05-16 | A kind of Recombinant Swine Interferon α1-Fc fusion rotein and encoding gene thereof and expression method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103232545B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570836A (en) * | 2013-10-25 | 2014-02-12 | 江苏众红生物工程创药研究院有限公司 | Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof |
CN107082814A (en) * | 2017-06-12 | 2017-08-22 | 扬州大学 | A kind of long-acting interferon and preparation method thereof |
CN107254482A (en) * | 2017-07-18 | 2017-10-17 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon alpha fusion protein antiviral activity |
CN107326037A (en) * | 2017-07-18 | 2017-11-07 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967196A (en) * | 2010-11-10 | 2011-02-09 | 夏志南 | Interferon fusion protein, preparation thereof and application thereof |
CN103059122A (en) * | 2013-01-23 | 2013-04-24 | 江苏众红生物工程创药研究院有限公司 | Recombined porcine interferon alpha 1, as well as gene encoding gene and expression method thereof |
CN103087200A (en) * | 2013-01-28 | 2013-05-08 | 江苏众红生物工程创药研究院有限公司 | Pig IFN (interferon) gamma-Fc fusion protein as well as coding gene and expression method of pig IFN (interferon) gamma-Fc fusion protein |
-
2013
- 2013-05-16 CN CN201310182855.6A patent/CN103232545B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967196A (en) * | 2010-11-10 | 2011-02-09 | 夏志南 | Interferon fusion protein, preparation thereof and application thereof |
CN103059122A (en) * | 2013-01-23 | 2013-04-24 | 江苏众红生物工程创药研究院有限公司 | Recombined porcine interferon alpha 1, as well as gene encoding gene and expression method thereof |
CN103087200A (en) * | 2013-01-28 | 2013-05-08 | 江苏众红生物工程创药研究院有限公司 | Pig IFN (interferon) gamma-Fc fusion protein as well as coding gene and expression method of pig IFN (interferon) gamma-Fc fusion protein |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570836A (en) * | 2013-10-25 | 2014-02-12 | 江苏众红生物工程创药研究院有限公司 | Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof |
CN103570836B (en) * | 2013-10-25 | 2016-03-16 | 江苏众红生物工程创药研究院有限公司 | A kind of Recombinant Swine interferon beta 1-Fc fusion rotein and encoding gene thereof and expression method |
CN107082814A (en) * | 2017-06-12 | 2017-08-22 | 扬州大学 | A kind of long-acting interferon and preparation method thereof |
CN107254482A (en) * | 2017-07-18 | 2017-10-17 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon alpha fusion protein antiviral activity |
CN107326037A (en) * | 2017-07-18 | 2017-11-07 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity |
Also Published As
Publication number | Publication date |
---|---|
CN103232545B (en) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103570836B (en) | A kind of Recombinant Swine interferon beta 1-Fc fusion rotein and encoding gene thereof and expression method | |
CN103059124A (en) | Recombined porcine interferon Gamma, coding gene thereof and expressing method | |
CN103087200A (en) | Pig IFN (interferon) gamma-Fc fusion protein as well as coding gene and expression method of pig IFN (interferon) gamma-Fc fusion protein | |
CN106282216A (en) | A kind of preparation method of recombinant long-acting chicken interferon α | |
CN104894065A (en) | NK (natural killer) cell culture medium and culture method of NK cell | |
CN103232545A (en) | Recombination porcine interferon alpha1-Fc fusion protein as well as coding gene and expression method thereof | |
CN105949323A (en) | EpCAM-specific chimeric antigen receptor and encoding gene and application thereof | |
CN103319608B (en) | Pig IFNalpha1-Fc fusion protein as well as encoding gene and expression method thereof | |
CN103265637B (en) | A kind of Recombinant Swine IL-4-Fc fusion rotein and encoding gene thereof and expression method | |
CN103232544B (en) | Recombination porcine interferon gamma-Fc fusion protein as well as coding gene and expression method thereof | |
CN103936862A (en) | Co-expression of fusion porcine interleukin 4/6 and interleukin 2 genes and application of fusion porcine interleukin 4/6,2 gene in preparation of biological agents | |
CN103012577B (en) | Recombinant porcine interleukin 4, and encoding gene and expression method thereof | |
CN106399266A (en) | Recombinant baculovirus for expressing dog serum albumin fused interferon gamma and application of recombinant baculovirus | |
CN103059122B (en) | Recombined porcine interferon alpha 1, as well as gene encoding gene and expression method thereof | |
CN105384826A (en) | Cord blood nucleated cell for expressing chimeric antigen receptor and application of cord blood nucleated cell | |
CN103012578B (en) | Recombinant porcine interleukin 2, and encoding gene and expression method thereof | |
CN101544693B (en) | Recombined extrasin alpha 1 two-strand body protein and preparation method thereof | |
CN108948163A (en) | Queensland nut plant alexin and its application | |
CN103276003A (en) | Immunological regulation type chicken E.tenella resistant recombinant lactobacillus and preparation method thereof | |
CN103495159B (en) | The preparation method of flavobacterium columnare genetic vaccine | |
CN103509100B (en) | Interleukin-1 receptor antagonist mutant | |
CN103059123B (en) | A kind of recombinant porcine interferon beta 1 and its coding gene and expression method | |
CN102660579A (en) | HBx and human IL-12 double-gene recombinant vector and liver caner-resistant vaccine | |
CN102978214B (en) | Chicken-gamma-interferon gene sequence, recombinant engineering bacteria and application thereof | |
CN107177539A (en) | A kind of Schistosoma japonicum and lockjaw bivalent be oral or collunarium vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Patentee after: ZonHon Biopharma Institute Inc. Patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Patentee before: ZonHon Biopharma Institute Inc. Patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Co-patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP02 | Change in the address of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190514 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right |